Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Eagle Biologics

Eagle Biologics
2013 FOUNDED
M&A STATUS
M&A LATEST DEAL TYPE
$78M LATEST DEAL AMOUNT
Description

Operator of a biopharmaceutical agency intended to develop innovative protein formulation. The company's biopharmaceutical agency produces high-concentration drugs and related products with low viscosity, suitable for small-volume subcutaneous injection, enabling clients to avail improved access to highly viscous protein therapeutics.

Website
Formerly Known As
Arsia Therapeutics
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Delivery
Primary Office
  • Kendall Square
  • Cambridge, MA
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Eagle Biologics’s full profile, request a free trial.

Eagle Biologics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 11-Nov-2016 $78M 0000 Completed Generating Revenue
2. Early Stage VC Completed Startup
1. Accelerator/Incubator Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Eagle Biologics Competitors (10)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ReForm Biologics Venture Capital-Backed Cambridge, MA 00000 00000
000000 Private Equity-Backed Cambridge, United Kingdom 000 000.00 000000000000 000.00
000000000 Venture Capital-Backed Newcastle upon Tyne, United Kingdom 00 00000 0000000000 0 00000
00000000 Venture Capital-Backed Saffron Walden, United Kingdom 00 00.000 0000000000 00.000
0000000 0000000000 Formerly VC-backed Cambridge, United Kingdom 00 00000 00000000 00000
To view this company’s complete list of competitors, request access »

Eagle Biologics Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
JLABS Accelerator/Incubator 000 0000 000000 0
Polaris Partners Venture Capital Minority 000 0000 000000 0

Eagle Biologics Executive Team (5)

Name Title Board
Seat
Contact
Info
Kevin Love Director, Business Development & Operations
Charles Wescott Ph.D Vice President of Research & Development
Alexander Klibanov Co-Founder
Robert Langer Ph.D Co-Founder

1 Former Executive

You’re viewing 4 of 5 executives. Get the full list »